Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 25-30

  Byrne, Michael J ^a   Davidson, J A ^a   Musk, A W ^a   Dewar, J ^a   Van Hazel, G ^a   Buck, M ^a   De Klerk, N H ^a   Robinson, B W S ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESOTHELIOMA; NAUSEA; PHASE 2 CLINICAL TRIAL; PLEURA TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; VOMITING;

EID: 0032895398     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.25     Document Type: Article

References (22)

1. Musk AW, Dolin PJ, Armstrong BK, et al: The incidence of malignant mesothelioma in Australia, 1947-1980. Med J Aust 150:242-246, 1989
2. Musk AW, Woodward SD: Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia. Aust N Z J Med 12:229-232, 1982
3. Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 14:1007-1017, 1996
4. Upham J, Musk AW, van Hazel G, et al: Interferon alfa and doxorubicin in malignant mesothelioma: A phase II study. Aust N Z J Med 23:683-687, 1993
5. Davidson JA, Robinson BWS: Gemcitabine activity on murine and human malignant mesothelioma cell lines show additive activity in combination with cisplatin. Aust N Z J Med 27:213, 1997
6. Sandler A, Ansari R, McClean J, et al: Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study. Eur J Cancer 31A:S225, 1995 (suppl 5, abstr 1079)
7. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15:744-749, 1997
8. Crino L, Seagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15: 297-303, 1997
9. Hermanek P, Sobin LH (eds): TNM Classification of Malignant Tumours (ed 4. revision 2). Berlin, Germany, Springer-Verlag, 1992
10. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
11. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
12. Colbert N, Vannetzel JM, Izrael V, et al: A prospective study of detorubicin in malignant mesothelioma. Cancer 56:2170-2174, 1985
13. Solheim OP, Saeter G, Finnanger AM, et al: High dose methotrexate in the treatment of malignant mesothelioma of the pleura: A phase II study. Br J Cancer 65:956-960, 1992
14. Belani CP, Herdon J, Vogelzang NJ, et al: Edatrexate for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9131). Proc Am Soc Clin Oncol 13:329, 1994 (abstr)
15. Mintzer DM, Kelsen D, Frimmer D: Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711-718, 1985
16. Zidar BL, Green S, Pierce HI, et al: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 6:223-226, 1988
17. Van Meerbeeck JP, Baas P, Debruyne C, et al: Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study. Lung Cancer 18:17, 1997 (suppl 1)
18. Millard FE, Herndon J, Vogelzang MR, et al: Gemcitabine for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9530). Proc Am Soc Clin Oncol 16:1710, 1997
19. Bischoff HG, Manegold C, Knopp M, et al: Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17:1784, 1998
20. Breau JL, Boaziz C, Morere JJF, et al: Combination chemotherapy with cisplatinum, adriamycin, bleomycin and mitomycin C plus systemic and intrapleural hyaluronidase in 25 consecutive cases of stages II, III pleural mesothelioma. First International Mesothelioma Conference, Paris, France, 1991 (abstr 15)
21. Trandafir L, Borel C, Ruffie P, et al: Combined systemic CDDP-interferon alfa (IFN) in advanced pleural malignant mesothelioma. Proc Am Soc Clin Oncol 13:405, 1994
22. Middleton GW, Verrill MW, Priest K, et al: Good symptom relief with palliative MVP (mitomycin C, vinblastine, cisplatin) chemotherapy in malignant mesothelioma. Lung Cancer 18:22, 1997 (suppl 1)